Xia Wei, Nagase Satoru, Montia Amy Gerstein, Kalachikov Sergey M, Keniry Megan, Su Tao, Memeo Lorenzo, Hibshoosh Hanina, Parsons Ramon
Institute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Cancer Res. 2008 Mar 15;68(6):1667-74. doi: 10.1158/0008-5472.CAN-07-5276.
Screening for tumor suppressor genes in breast cancer revealed multiple truncating mutations of PB1, which encodes the BAF180 subunit of the PBAF chromatin remodeling complex. Mutation was associated with loss of heterozygosity of the wild-type allele. BAF180 complementation of BAF180-mutant tumor cells caused G(1) arrest that was dependent on increased expression of the cyclin/cyclin-dependent kinase inhibitor p21/WAF1/CIP1. Endogenous wild-type BAF180 bound to the p21 promoter and was required for proper p21 expression and G(1) arrest after transforming growth factor-beta and gamma-radiation treatment. BAF180 thus functions on two tumor suppressor signaling pathways as a physiologic mediator of p21 expression. We conclude that BAF180 suppresses tumorigenesis, at least in part, through its ability to regulate p21.
在乳腺癌中筛查肿瘤抑制基因时发现,PB1存在多个截短突变,PB1编码PBAF染色质重塑复合物的BAF180亚基。突变与野生型等位基因杂合性缺失相关。用BAF180对BAF180突变的肿瘤细胞进行互补,会导致G(1)期阻滞,这依赖于细胞周期蛋白/细胞周期蛋白依赖性激酶抑制剂p21/WAF1/CIP1表达的增加。内源性野生型BAF180与p21启动子结合,在转化生长因子-β和γ射线处理后,对于p21的正常表达和G(1)期阻滞是必需的。因此,BAF180作为p21表达的生理介质,在两条肿瘤抑制信号通路中发挥作用。我们得出结论,BAF180至少部分地通过其调节p21的能力来抑制肿瘤发生。